> ## Content Index > Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt > Use this file to discover other available public pages before exploring further. # Krishna Institute of Medical Sciences Moat Analysis: Score & Risks - URL: https://www.moatmarginresearch.com/krishna-institute-of-medical-sciences-moat/ - Published: 2026-08-16T18:04:17.000Z - Updated: 2026-08-22T05:13:03.000Z - Author: A K Karthikeyan - Tags: First-pass note, Coverage Moat Note · First-pass ## Krishna Institute of Medical Sciences Ltd. A first-pass moat teardown of Krishna Institute of Medical Sciences Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it. **Moat & Margin**16 Aug 2026 First-pass · \~3 min 4.28 / 10 NARROWProcess/Data-led First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence. Provisional score · subject to modification based on new evidence Krishna Institute of Medical Sciences Ltd. scores **4.28** on MoatSCORE 6.0 — a narrow moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued. The teardown ## Seven dimensions of moat Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome. D3Cost Advantage4.8 M · Mechanism✓ Verified verbatim “total revenue on standalone basis decreased by 1.03% to Rs. 11,555.20 million in FY23 compared to Rs. 11,675.50 million in the previous year” **Krishna Institute of Medical Sciences Ltd.** · Annual Report · p.22 D6Efficient Scale4.8 M · Mechanism✓ Verified verbatim “EBITDA margin stood at 20.4% versus 25.9% in Q3 FY 25 and 21.6% in Q2 FY 26” **Krishna Institute of Medical Sciences Ltd.** · Earnings Call · p.3 D1Network Effects4.7 M · Mechanism✓ Verified verbatim “These new assets are not just additions to our network; they are gateways to serving millions of new patients and establishing KIMS as a pan-Indian healthcare provider.” **Krishna Institute of Medical Sciences Ltd.** · Annual Report · p.12 D4Price Discretion4.7 M · Mechanism✓ Verified verbatim “Mr. Vikas Maheshwari Chief Financial Officer (Resigned w.e.f. 01.06.2023)” **Krishna Institute of Medical Sciences Ltd.** · Annual Report · p.4 D5Intangible Assets4.7 O · Outcome✓ Verified verbatim “I just have 1 more additional question. So just want to understand what is plan to reduce promoter pledge like right now, there is notable pledging of promoter stake” **Krishna Institute of Medical Sciences Ltd.** · Earnings Call · p.12 1 quote extracted here — not one mechanism-class. The evidence is outcome-only. D2Switching Costs4.5 No verified filing quote surfaced for this dimension in the first-pass evidence sweep. D7Counter-PositioningExcluded— Excluded for this archetype. D8Ungoverned RiskUnscored · Layer 2.5 D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed. The barrier gate ## The barrier gate — first-pass Replication — can a rival copy it?5.0 How hard it is for a rival to copy the edge (first-pass estimate). Bypass — can a rival route around it?5.0 How easily a rival can route around the edge (first-pass estimate). Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate. What would change our mind 1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read. 2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band. 3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window. First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser. **Where this note fits.** This company is one of **509 Indian companies** we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).